PD65-05 URINE EXPRESSION OF TIMP1, SERPINB1, AND SEMENOGELIN 2 MAY DIFFERENTIATE MEN WITH LOW-RISK OR NO EVIDENCE OF PROSTATE CANCER FROM MEN WITH HIGH-RISK OR METASTATIC DISEASE

Abstract

Listen

Translate article

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2017PD65-05 URINE EXPRESSION OF TIMP1, SERPINB1, AND SEMENOGELIN 2 MAY DIFFERENTIATE MEN WITH LOW-RISK OR NO EVIDENCE OF PROSTATE CANCER FROM MEN WITH HIGH-RISK OR METASTATIC DISEASE Sarah Prophet, Adam Feldman, Mary Fergus, and Bruce Zetter Sarah ProphetSarah Prophet More articles by this author , Adam FeldmanAdam Feldman More articles by this author , Mary FergusMary Fergus More articles by this author , and Bruce ZetterBruce Zetter More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2955AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES While serum PSA and other available diagnostic biomarkers can provide valuable guidance for assessing the risk of prostate cancer (PCa), limitations in accuracy persist. Novel biomarkers with improved performance characteristics are needed. Using mass spectrometry-based proteomics, we have identified three urinary proteins with significantly different expression patterns across PCa stages. This study evaluates the expression of these potential biomarkers in urine. METHODS Urinary protein concentrations of three proteins, TIMP1, serpinB1, and semenogelin 2, were assessed via Western blot and ELISA for 160 total urine samples. Each patient group (control, Gleason 6 PCa, Gleason ≥8 PCa, and metastatic PCa) had 40 samples. Urine protein was isolated using Amicon Ultra-15 Centrifugal Filter Units for Western blotting. ELISAs were performed using untreated raw urine samples. Immunohistochemistry (IHC) was performed on prostate tissue sections for all three proteins of interest. RESULTS TIMP1 levels were statistically higher in control and Gleason 6 PCa urine samples than for Gleason ≥8 and metastatic disease (2.19 ± 1.7 vs. 1.23 ± 1.13 ng/mL; p = 0.002). Expression of serpinB1 was significantly higher in men with Gleason 6 PCa than those with high-grade Gleason ≥8 PCa (0.71 ± 0.49 vs. 0.23 ± 0.33 ng/mL; p = 0.003). Metastatic PCa had significantly higher semenogelin2 concentrations in urine than healthy men (155.68 ± 74.3 vs. 81.55 ± 55.6 pg/mL; p = 0.02), and expression levels seem to rise with disease progression. IHC staining of tissue sections corroborated these findings. CONCLUSIONS Our results indicate differences in urinary concentrations of TIMP1, serpinB1, and semenogelin 2 across PCa stages. These novel biomarkers allowed distinction between men without prostate cancer or low-risk disease and those with high-risk or metastatic disease. These proteins represent potentially valuable non-invasive prostate cancer biomarkers and warrant further investigation. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1268 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Sarah Prophet More articles by this author Adam Feldman More articles by this author Mary Fergus More articles by this author Bruce Zetter More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...